Australia’s TGA Clears ResApp Health’s Wearable Cough Monitor

ResApp Health has received clearance from Australia’s Therapeutic Goods Administration (TGA) for its wearable cough-monitoring system.

The clip-on device provides 24/7 monitoring of a patient using an algorithm to analyze cough sounds. It identifies more than 93 percent of cough events and has a false-positive rate of less than 1 percent.

Brisbane-based ResApp said it plans to explore the device’s capabilities and first intends to put the device through clinical trials to evaluate its ability to measure cough frequency.